Figure 1 LAAM
The following sections of this BookRags Literature Study Guide is offprint from Gale's For Students Series: Presenting Analysis, Context, and Criticism on Commonly Studied Works: Introduction, Author Biography, Plot Summary, Characters, Themes, Style, Historical Context, Critical Overview, Criticism and Critical Essays, Media Adaptations, Topics for Further Study, Compare & Contrast, What Do I Read Next?, For Further Study, and Sources.
(c)1998-2002; (c)2002 by Gale. Gale is an imprint of The Gale Group, Inc., a division of Thomson Learning, Inc. Gale and Design and Thomson Learning are trademarks used herein under license.
The following sections, if they exist, are offprint from Beacham's Encyclopedia of Popular Fiction: "Social Concerns", "Thematic Overview", "Techniques", "Literary Precedents", "Key Questions", "Related Titles", "Adaptations", "Related Web Sites". (c)1994-2005, by Walton Beacham.
The following sections, if they exist, are offprint from Beacham's Guide to Literature for Young Adults: "About the Author", "Overview", "Setting", "Literary Qualities", "Social Sensitivity", "Topics for Discussion", "Ideas for Reports and Papers". (c)1994-2005, by Walton Beacham.
All other sections in this Literature Study Guide are owned and copyrighted by BookRags, Inc.
Acetylmethadol (also referred to as l-alpha-acetylmethadol, methadyl acetate, LAAM or L-AAM) is structurally related to METHADONE. LAAM is a potent OPIOID agonist with properties similar to methadone, except for its prolonged half-life. This slow elimination can be useful clinically, since 50-80 milligram doses of LAAM given three times a week are equivalent to daily doses of 50-100 milligrams of methadone in preventing the symptoms of opioid WITHDRAWAL. Thus, addicts on maintenance treatment would need to come to a clinic only three times a week for LAAM instead of daily for methadone. Since the early 1970s, methadone has been the only agent approved for use in maintenance-treatment programs for HEROIN addicts, but research has shown that LAAM can be a useful alternative. In 1993, the U.S. Food and Drug Administration (FDA) initiated the legal changes needed to make LAAM available for clinical use.
Figure 1 LAAM
GILMAN, A. G., ET AL. (EDS.). (1990). Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon.
GREENSTEIN, R. A., FUDALA P. J., & O' BRIEN, C.P. (1992). Alternative pharmacotherapies for opiate addiction. In J. H. Lowinson, P. Ruiz, & R. B. Millman (Eds.), Substance abuse: A comprehensive textbook, 2nd ed. Baltimore: Williams & Wilkins.